For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231229:nRSc2342Ya&default-theme=true
RNS Number : 2342Y Genedrive PLC 29 December 2023
genedrive plc
("genedrive" or the "Company")
Result of AGM
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company,
announces that at the Annual General Meeting, held today, all resolutions
proposed were duly passed.
For information, details of the proxy voting are shown below:
Resolution Votes For Votes For Votes Against Votes Against Vote Withheld
(as % of votes cast) (as % of votes cast)
1 9,120,276 98.8% 113,243 1.2% 199,069
2 8,958,874 97.0% 274,645 3.0% 199,069
3 8,949,212 97.3% 243,769 2.7% 239,607
4 8,958,212 97.4% 234,769 2.6% 239,607
5 7,803,515 97.1% 234,769 2.9% 1,394,304
6 9,075,202 98.4% 143,117 1.6% 214,269
7 8,983,550 97.5% 234,769 2.5% 214,269
8 9,061,602 98.3% 156,717 1.7% 214,269
9 9,085,116 98.6% 126,403 1.4% 221,069
10 8,962,881 96.1% 364,153 3.9% 105,554
11 7,805,054 83.7% 1,519,780 16.3% 107,754
12 8,968,751 96.2% 355,723 3.8% 108,114
13 8,962,881 96.1% 364,153 3.9% 105,554
14 8,960,351 96.1% 364,483 3.9% 107,754
The full text of each of the resolutions is set out in the notice of Annual
General Meeting, copies of which are available on the Company's website
(www.genedriveplc.com (http://www.genedriveplc.com/) ).
For further details please contact:
genedrive plc +44 (0)161 989 0245
James Cheek: CEO / Russ Shaw: CFO
Peel Hunt LLP (Nominated Adviser and Broker) +44 (0)20 7418 8900
James Steel / Patrick Birkholm
Walbrook PR Ltd (Media & Investor Relations) +44 (0)20 7933 8780 or genedrive@walbrookpr.com
(mailto:genedrive@walbrookpr.com)
Anna Dunphy +44 (0)7876 741 001
About genedrive plc (http://www.genedriveplc.com
(http://www.genedriveplc.com/) ) genedrive plc is a pharmacogenetic testing
company developing and commercialising a low cost, rapid, versatile, simple to
use and robust point of need pharmacogenetic platform for the diagnosis of
genetic variations. This helps clinicians to quickly access key genetic
information that will help them make the right choices over the right medicine
or dosage to use for an effective treatment. Based in the UK, the Company is
at the forefront of work on Point of Care pharmacogenetics. Pharmacogenetics
looks at how your genetics impacts a medicines ability to work for you.
Therefore, by using pharmacogenetics, medicines can be made safer and more
effective. The Company has launched its flagship product, the Genedrive®
MT-RNR1 ID Kit, which is a single-use disposable cartridge which circumvents
the requirement for cold chain logistics by providing temperature stable
reagent test kits for use on their proprietary test platform. This test allows
clinicians to make a decision on antibiotic use within 26 minutes, ensuring
vital care is delivered with no negative impact on the patient pathway.
The Company has a clear commercial strategy focused on accelerating growth
through maximising in-market sales, geographic and portfolio expansion and
strategic M&A, and operates out of its facilities in Manchester.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END RAGBBBDDXSDDGXC